Developing scalable cell replacement therapies for the world

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treat incurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety.

We are also establishing processes for manufacturing and controls and instituting GMP manufacturing and GLP studies to cater to market needs worldwide. Our lead product out of the platform is EyecyteRPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. We are currently targeting phase-one trials for EyecyteRPE in the later half of 2020.

Recent Scientific Papers

Proud to see Eyestem Chief Scientist Dr Rajarshi Pal as a speaker at a Taylor U (Malaysia) workshop on EyecyteRPE for Dry AMD and the future of Regenerative Medicine | Prima Nexus.

A big step towards regulating the cell therapy ecosystem !

Career Openings

Research Scientist

Project: Genome engineering of induced pluripotent stem cells and or their differentiated derivatives

Research Associate

Project: Generation of transplantable photoreceptors from induced pluripotent stem cells for the treatment of retinitis pigmentosa

View all